Background Poorly differentiated thyroid cancer (PDTC) is a rare, follicular cell-derived
neoplasm with an unfavorable prognosis. The oncocytic variant of PDTC may be associated …

Objectives The understanding of the mechanisms underlying thyroid cancer immune escape
can lead to the identification of new molecular targets and/or efficacy biomarkers. For this …

Although papillary thyroid cancer (PTC) is curable with excellent survival rate, patients with
dedifferentiated PTC suffer the recurrence or death. As cancer immune escape plays a …

Papillary thyroid carcinoma (PTC) represents a heterogeneous disease with diverse clinical
outcomes highlighting a need to identify robust biomarkers with clinical relevance. We …

Thyroid cancer (THCA) is a heterogeneous disease with multiple clinical outcomes Immune
cells regulate its progression. Three immunomolecular subtypes (C1, C2, C3) were …

Background Immune cells account for a large proportion of the tumour microenvironment in
anaplastic thyroid carcinomas (ATCs). However, the expression pattern of immune-related …

Papillary thyroid carcinoma (PTC) variants exhibit different prognosis, but critical
characteristics of PTC variants that contribute to differences in pathogenesis are not well …

Poorly differentiated thyroid carcinoma (PDTC), defined by Turin criteria, comprises a subset
of high-grade follicular-derived thyroid carcinomas with intermediate prognosis. While …

Purpose Increasing evidence indicates that there is a correlation between papillary thyroid
carcinoma (PTC) prognosis and the immune signature. Our goal was to construct a new …

Background Cuproptosis, a new form of programmed cell death, has been recently reported
to be closely related to tumor progression. However, the significance of cuproptosis-related …